4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)-N-[((5R)-2-oxo-3-{5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl}-1,3-oxazolidin-5-yl)methyl]benzamide | 1093752-62-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)-N-[((5R)-2-oxo-3-{5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl}-1,3-oxazolidin-5-yl)methyl]benzamide
• 英文别名: (R)-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((2-oxo-3-(5-(2-(trifluoromethoxy)phenyl)pyridin-2-yl)oxazolidin-5-yl)methyl)benzamide；4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-N-[[(5R)-2-oxo-3-[5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl]-1,3-oxazolidin-5-yl]methyl]benzamide
• CAS: 1093752-62-5
• 化学式: C₃₄H₂₆F₃N₅O₅
• 分子量: 641.606
• InChiKey: VIKKXFYHSNSWKV-XMMPIXPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  47
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  4-氯甲酰基苯甲酸甲酯 在 四(三苯基膦)钯 、 palladium 10% on activated carbon 草酰氯 、 lithium hydroxide monohydrate 、 氢气 、 sodium carbonate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 20.0~150.0 ℃ 、68.95 kPa 条件下， 反应 5.67h， 生成 4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)-N-[((5R)-2-oxo-3-{5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl}-1,3-oxazolidin-5-yl)methyl]benzamide
  参考文献：
  名称：

  WO2008/156718

  摘要：

  公开号：

文献信息

• CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES
  申请人：Hunt Julianne A.

  公开号：US20100184719A1

  公开（公告）日：2010-07-22

  Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.

  具有公式I结构的化合物，包括化合物的药学上可接受的盐，是有效的CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。 在公式I中，A-B是芳香酰胺基团。
• CETP inhibitors derived from benzoxazole arylamides
  申请人：Merck Sharpe & Dohme Corp.

  公开号：US08293721B2

  公开（公告）日：2012-10-23

  Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.

  具有I式结构的化合物，包括该化合物的药物可接受的盐，是有效的CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。在公式I中，A-B是芳基酰胺基团。
• 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Attenuation of hERG binding and improved HDLc-raising efficacy
  作者：Ramzi F. Sweis、Julianne A. Hunt、Peter J. Sinclair、Ying Chen、Suzanne S. Eveland、Qiu Guo、Sheryl A. Hyland、Denise P. Milot、Anne-Marie Cumiskey、Melanie Latham、Raymond Rosa、Larry Peterson、Carl P. Sparrow、Matt S. Anderson

  DOI：10.1016/j.bmcl.2011.02.049

  日期：2011.5

  The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Efforts focused on finding suitable replacements for the central piperidine with the aim of reducing hERG binding: a main liability of our benchmark benzoxazole (1a). Replacement of the piperidine with a cyclohexyl group successfully attenuated hERG binding, but was accompanied by reduced in vivo efficacy. The approach of substituting a piperidine moiety with an oxazolidinone also attenuated hERG binding. Further refinement of this latter scaffold via SAR at the pyridine terminus and methyl branching on the oxazolidinone led to compounds 7e and 7f, which raised HDLc by 33 and 27 mg/dl, respectively, in our transgenic mouse PD model and without the hERG liability of previous series. (C) 2011 Elsevier Ltd. All rights reserved.
• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：DalCor Pharma UK Ltd Leatherhead, Zug Branch

  公开号：EP3833336A1

  公开（公告）日：2021-06-16
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.